Monthly treatment with dasatinib (5 mg/kg) and quercetin (50 mg/kg) prevented alveolar bone loss in aged mice over 10 months, while also preserving femoral cortical bone microarchitecture and downregulating inflammatory genes IL-6, MMP13, and LAMB1. However, weekly dosing failed to protect against ligature-induced periodontitis in younger rats. This divergent outcome illuminates a crucial distinction in senolytic therapy applications. Age-related bone loss stems from chronic accumulation of senescent cells that secrete inflammatory factors, creating an ideal target for senolytics like dasatinib-quercetin combinations. Active periodontal disease involves acute bacterial infection and rapid tissue destruction that may overwhelm senolytic benefits or require different intervention timing. The finding adds dental health to the growing list of age-related conditions where senolytics show promise, joining osteoarthritis, cardiovascular disease, and cognitive decline. For aging adults, this suggests potential preventive benefits for oral health, though human trials remain essential. The limitation lies in the mouse model and monthly dosing schedule, which may not translate directly to human periodontal maintenance. The research confirms senolytics work best against chronic age-related inflammation rather than acute infectious processes.